Stryker Corp. (SYK)

This is a long-term Hold. He recently added to his holdings. This is your hip, knees, ankles, feet, prosthetics. You are paying a little bit more for their growth. This is going to be the wave of the future. Feels they are capturing market share.

(Top Pick Feb 25/16, Up 21.75%) He is not chasing high flying pharma, but the more steady, boring ones that people use more and more as they age. They grow by acquisition.

When it comes to healthcare stocks, you have to differentiate between those pharmaceuticals that have very good margins without any threat to their profit margins, and a stock like this that makes implants. In the field of implants, there has been very little innovation in the last 10 years, and he thinks problems are going to come from both Medicare and Medicaid. Thinks they are going to be pushing prices down, not up, which is a threat to the implant manufacturers.

(A Top Pick Feb 25/16. Up 14.39%.) Hospital equipment. The growth drivers are charged by the demographics, but also having really high quality equipment, and making strategic acquisitions to integrate itself into the hospital industry structure in a better way. (Wouldn’t buy at current prices, but wait for a 10% pullback at least.)

Demographically this is really positive. Mr. Trump and Mrs. Clinton debate doesn’t factor into a company like this. They make knees and hips, and are into shoulders a bit now. They now include technology so that if a hip has problems, it can send a message. A little expensive, but a good grower and there is room for acquisitions.

Thinks this is a probably going to be a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

Healthcare is the only sector that has both top line and earnings growth. Hospital beds, hip and knee replacements. They are geared to the aging demographic.

This is down from its highs and is a good story.

(A Top Pick Jan 28/14. Up 5.15%.) Loves the company. Very innovative. They are introducing more technology in the operating room. Not only providing the product that goes into your body, but also building the robot that assists the doctor that performed the surgery. Has a great 5 year track record of increasing its dividend. Good strong balance sheet. Strong international sales. Still a Buy.

(A Top Pick April 7/14. Up 21.7%.) The healthcare sector is kind of fragmented into biotech, pharmaceutical and equipment. His view on the equipment side is quite constructive. Demographics are positive. Also, you don’t have the regulatory side that you have with the drugs.

(A Top Pick April 7/14. Up 13.91%.) Part of this company is focused on technology. They are known as the knees and hips type of company. Going forward, this offers a ton of opportunities, anywhere from demographics to healthcare. Good balance sheet and good management team.

Joint replacements. A great international growth story. The rising middle class globally will be spending more money on health care, so it is a good longer-term global story. Strong balance sheet. Very high return on equity at around 18%-19% consistently. Growing their dividend at around 25% compounded over the last 3-4 years.

(A Top Pick Nov 19/13. Up 27.13%.) Have recently made acquisitions on the technology side. Longer-term, this company is in great shape.

(A Top Pick Dec 5/13. Up 24.4%.) Fantastic history of increasing the dividend. Well-run company. Good international growth profile. Strong balance sheet. Trading at a very reasonable valuation. A good, long-term growth stock.

(A Top Pick Nov 19/13. Up 20.73%.) Artificial hips, joints etc. There has been some consolidation and there will be more. This is one of the bigger names, so they could be the buyer. Technology is playing a big role. Demographics will play a big role in this. He is also looking at other names in this space.